Acadia Pharmaceuticals Q3 revenue rises 23% on DAYBUE and NUPLAZID sales
Overview
Neurology drugmaker's Q3 revenue rose 23% yr/yr, driven by DAYBUE and NUPLAZID sales
DAYBUE Q3 net sales up 39% yr/yr; NUPLAZID sales up 14% yr/yr
Company raised 2026 DAYBUE sales guidance and narrowed total revenue and NUPLAZID ranges
Outlook
Company revises 2026 total revenue guidance to $1.265–$1.295 bln from $1.24–$1.30 bln
DAYBUE 2026 net sales guidance raised to $505–$520 mln from $480–$510 mln
NUPLAZID 2026 net sales guidance narrowed to $760–$775 mln from $760–$790 mln
Result Drivers
DAYBUE STIX UPTAKE - Co said strong uptake of DAYBUE STIX drove 39% yr/yr growth in DAYBUE sales
NUPLAZID DEMAND - Co attributed NUPLAZID sales growth to underlying demand and expanded commercial reach
EUROPEAN LAUNCH - Co cited initial momentum from DAYBU launch in Germany as contributing to results
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenues | $342.29 mln | ||
Q3 EPS | $0.31 | ||
Q3 Net Income | $53.52 mln | ||
Q3 Operating Expenses | $270.57 mln | ||
Q3 Pretax Profit | $80.44 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Acadia Pharmaceuticals Inc. is $31.92, about 55.2% above its November 3 closing price of $20.57
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 40 three months ago
Reuters Recommended Reads
Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand
Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised
Nov 3 - Amgen Q3 revenue beats expectations on higher volumes
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)